Philip Morris Launches New "IQOS ILUMA i" Series Devices in Japan

PMI by 2FIRSTS.ai
Apr.19.2024
Philip Morris Launches New "IQOS ILUMA i" Series Devices in Japan
Philip Morris Japan has launched the new "IQOS ILUMA i" series devices, available online and in convenience stores nationwide.

According to Japanese media Kakaku, on April 19th, global tobacco giant Philip Morris' Japanese company launched the new "IQOS ILUMA i" series devices, which are now available for purchase online and in convenience stores.

 

According to the media report, since March 2024, the "ILUMA i" series has been available for purchase on the IQOS online store, official IQOS online accounts, and seven IQOS stores nationwide (some Yamada Denki stores, some Bic Camera stores). Starting from April 16th, major chain convenience stores and some tobacco retailers across Japan will also begin selling the product.

 

According to a statement from PMI, convenience stores will mainly sell the "ILUMA i" and "ILUMA i One", while the "ILUMA i Prime" will be exclusively available at 7-11 convenience stores starting from April 16th. All models are available in two colors: micro blue and midnight black.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Czech Republic to Tighten E-Cigarette Rules in December, Ban Candy Flavours and Cannabinoids
Czech Republic to Tighten E-Cigarette Rules in December, Ban Candy Flavours and Cannabinoids
Czech Republic will tighten regulations on the sale and labelling of e-cigarettes from December. Manufacturers will have seven months to sell existing stock, after which candy-flavoured or cannabinoid-containing e-cigarettes will be banned. A survey by the National Institute of Public Health (SZÚ) found that nearly 14% of the population used e-cigarettes in 2024 — almost triple the rate five years earlier.
Nov.18 by 2FIRSTS.ai
BAT Podcast with AACS CEO: Vape Policy Imbalance Fuels Australia’s Billion-Dollar Illicit Market
BAT Podcast with AACS CEO: Vape Policy Imbalance Fuels Australia’s Billion-Dollar Illicit Market
In BAT’s The Smokeless Word podcast, AACS CEO Theo Foukkare warned that high taxes and strict vape bans have fueled Australia’s AUD 10-billion illicit nicotine market and rising retail crime, urging urgent regulatory reform.
Oct.27 by 2FIRSTS.ai
Singapore tightens vape enforcement, mandates rehab for etomidate users
Singapore tightens vape enforcement, mandates rehab for etomidate users
Singapore’s Ministry of Health (MOH) and Health Sciences Authority (HSA) reported that from Sep 1 to Oct 12, 1,339 people were caught for vape-related offences, including 102 found in possession of etomidate-laced vapes.
Oct.17 by 2FIRSTS.ai
Malaysia's Perlis Customs seized more than 510,000 smuggled e-cigarettes, involving more than US$2.85 million
Malaysia's Perlis Customs seized more than 510,000 smuggled e-cigarettes, involving more than US$2.85 million
In August, Malaysia's Perlis Customs raided Kampung Kawlan, seizing 517,394 e-cig devices/accessories in a Padang Besar warehouse. Haul: over RM12m (≈US2.85m),unpaidtaxesRM2.6m(≈US620k); 19yo guard arrested. Probes: e-cigs for Thailand, arrived via KLIA, to cross border illegally (pickup/container truck or Kelantan if blocked). Case under 1967 Customs Act §133(1)(f): max RM500k (≈US$120k) fine/7yrs jail, or both.
Sep.22 by 2FIRSTS.ai
Ireland Considering Ban on Nicotine Pouches to Protect Youth, Says Chief Medical Officer
Ireland Considering Ban on Nicotine Pouches to Protect Youth, Says Chief Medical Officer
Ireland’s Department of Health is examining a ban on nicotine pouches to curb nicotine use among young people. Chief Medical Officer Prof. Mary Horgan said the ban could be included in amendments to the current tobacco bill.
Nov.10 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai